{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T20:53:32Z","timestamp":1790110412346,"version":"4.0.1"},"reference-count":55,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,1,28]],"date-time":"2023-01-28T00:00:00Z","timestamp":1674864000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1016\/j.vaccine.2023.01.062","type":"journal-article","created":{"date-parts":[[2023,2,3]],"date-time":"2023-02-03T15:19:07Z","timestamp":1675437547000},"page":"1638-1648","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["A bivalent form of nanoparticle-based dengue vaccine stimulated responses that potently eliminate both DENV-2 particles and DENV-2-infected cells"],"prefix":"10.1016","volume":"41","author":[{"given":"Mathurin","family":"Seesen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tuksin","family":"Jearanaiwitayakul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jitra","family":"Limthongkul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panuwat","family":"Midoeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panya","family":"Sunintaboon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sukathida","family":"Ubol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7446","key":"10.1016\/j.vaccine.2023.01.062_b0005","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1038\/nature12060","article-title":"The global distribution and burden of dengue","volume":"496","author":"Bhatt","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2023.01.062_b0010","unstructured":"World Health Organization. Dengue and severe dengue [Fact sheet] 2022 [Available from: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/dengue-and-severe-dengue."},{"issue":"16","key":"10.1016\/j.vaccine.2023.01.062_b0015","doi-asserted-by":"crossref","first-page":"6242","DOI":"10.1073\/pnas.0508391103","article-title":"Global traffic and disease vector dispersal","volume":"103","author":"Tatem Andrew","year":"2006","journal-title":"Proc Natl Acad Sci"},{"issue":"13","key":"10.1016\/j.vaccine.2023.01.062_b0020","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1056\/NEJMoa1506223","article-title":"Efficacy and Long-Term Safety of a Dengue Vaccine in Regions of Endemic Disease","volume":"373","author":"Hadinegoro","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2023.01.062_b0025","doi-asserted-by":"crossref","first-page":"165","DOI":"10.12688\/wellcomeopenres.15507.1","article-title":"Estimating the proportion of vaccine-induced hospitalized dengue cases among Dengvaxia vaccinees in the Philippines","volume":"4","author":"Flasche","year":"2019","journal-title":"Wellcome open research"},{"key":"10.1016\/j.vaccine.2023.01.062_b0030","doi-asserted-by":"crossref","first-page":"597","DOI":"10.3389\/fcimb.2020.572681","article-title":"Antibody-Dependent Enhancement: A Challenge for Developing a Safe Dengue Vaccine","volume":"10","author":"Shukla","year":"2020","journal-title":"Front Cell Infect Microbiol"},{"issue":"5979","key":"10.1016\/j.vaccine.2023.01.062_b0035","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1126\/science.1185181","article-title":"Cross-reacting antibodies enhance dengue virus infection in humans","volume":"328","author":"Dejnirattisai","year":"2010","journal-title":"Science (New York, NY)"},{"issue":"12","key":"10.1016\/j.vaccine.2023.01.062_b0040","doi-asserted-by":"crossref","first-page":"e924","DOI":"10.1371\/journal.pntd.0000924","article-title":"Subversion of Innate Defenses by the Interplay between DENV and Pre-Existing Enhancing Antibodies: TLRs Signaling Collapse","volume":"4","author":"Modhiran","year":"2010","journal-title":"PLoS Negl Trop Dis"},{"issue":"6","key":"10.1016\/j.vaccine.2023.01.062_b0045","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1086\/651018","article-title":"Mechanisms of Immune Evasion Induced by a Complex of Dengue Virus and Preexisting Enhancing Antibodies","volume":"201","author":"Ubol","year":"2010","journal-title":"J Infect Dis"},{"issue":"5","key":"10.1016\/j.vaccine.2023.01.062_b0050","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1016\/j.celrep.2018.10.006","article-title":"Genetic Variation between Dengue Virus Type 4 Strains Impacts Human Antibody Binding and Neutralization","volume":"25","author":"Gallichotte","year":"2018","journal-title":"Cell Rep"},{"issue":"1","key":"10.1016\/j.vaccine.2023.01.062_b0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2020.108226","article-title":"Antigenic Variation of the Dengue Virus 2 Genotypes Impacts the Neutralization Activity of Human Antibodies in Vaccinees","volume":"33","author":"Martinez","year":"2020","journal-title":"Cell Rep"},{"key":"10.1016\/j.vaccine.2023.01.062_b0060","doi-asserted-by":"crossref","unstructured":"Rabaa MA, Girerd-Chambaz Y, Duong Thi Hue K, Vu Tuan T, Wills B, Bonaparte M, et al. Genetic epidemiology of dengue viruses in phase III trials of the CYD tetravalent dengue vaccine and implications for efficacy. eLife. 2017;6:e24196 DOI: 10.7554\/eLife.24196.","DOI":"10.7554\/eLife.24196"},{"issue":"4","key":"10.1016\/j.vaccine.2023.01.062_b0065","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1586\/14760584.2016.1116948","article-title":"T cell immunity to dengue virus and implications for vaccine design","volume":"15","author":"Rivino","year":"2016","journal-title":"Expert Rev Vaccines"},{"issue":"3","key":"10.1016\/j.vaccine.2023.01.062_b0070","first-page":"223","article-title":"Th1\/Th2 balance: the hypothesis, its limitations, and implications for health and disease","volume":"8","author":"Kidd","year":"2003","journal-title":"Alternat Med Rev J Clin Therap"},{"issue":"11","key":"10.1016\/j.vaccine.2023.01.062_b0075","doi-asserted-by":"crossref","first-page":"e50387","DOI":"10.1371\/journal.pone.0050387","article-title":"Cellular and Cytokine Correlates of Severe Dengue Infection","volume":"7","author":"Malavige","year":"2012","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.vaccine.2023.01.062_b0080","doi-asserted-by":"crossref","first-page":"783","DOI":"10.4269\/ajtmh.2005.72.783","article-title":"TH2 IMMUNE RESPONSE IN PATIENTS WITH DENGUE DURING DEFERVESCENCE: PRELIMINARY EVIDENCE","volume":"72","author":"Mabalirajan","year":"2005","journal-title":"Am J Trop Med Hyg Am J Trop Med Hyg"},{"issue":"2","key":"10.1016\/j.vaccine.2023.01.062_b0085","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1586\/erv.09.139","article-title":"Domain III of the envelope protein as a dengue vaccine target","volume":"9","author":"Guzman","year":"2010","journal-title":"Expert Rev Vaccines"},{"issue":"23","key":"10.1016\/j.vaccine.2023.01.062_b0090","doi-asserted-by":"crossref","first-page":"12816","DOI":"10.1128\/JVI.00432-07","article-title":"Type- and Subcomplex-Specific Neutralizing Antibodies against Domain III of Dengue Virus Type 2 Envelope Protein Recognize Adjacent Epitopes","volume":"81","author":"Sukupolvi-Petty","year":"2007","journal-title":"J Virol"},{"issue":"2","key":"10.1016\/j.vaccine.2023.01.062_b0095","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.virol.2007.05.042","article-title":"Characterization of an antigenic site that contains a dominant, type-specific neutralization determinant on the envelope protein domain III (ED3) of dengue 2 virus","volume":"366","author":"Gromowski","year":"2007","journal-title":"Virology"},{"issue":"15","key":"10.1016\/j.vaccine.2023.01.062_b0100","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.1016\/j.vaccine.2022.02.070","article-title":"A novel chimeric dengue vaccine candidate composed of consensus envelope protein domain III fused to C-terminal-modified NS1 protein","volume":"40","author":"Huang","year":"2022","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2023.01.062_b0105","doi-asserted-by":"crossref","first-page":"2644","DOI":"10.3389\/fmicb.2017.02644","article-title":"Pichia pastoris-Expressed Bivalent Virus-Like Particulate Vaccine Induces Domain III-Focused Bivalent Neutralizing Antibodies without Antibody-Dependent Enhancement in Vivo","volume":"8","author":"Shukla","year":"2017","journal-title":"Front Microbiol"},{"key":"10.1016\/j.vaccine.2023.01.062_b0110","doi-asserted-by":"crossref","unstructured":"Wollner Clayton J, Richner M, Hassert Mariah A, Pinto Amelia K, Brien James D, Richner Justin M, et al. A Dengue Virus Serotype 1 mRNA-LNP Vaccine Elicits Protective Immune Responses. Journal of Virology.95(12):e02482-20 DOI: 10.1128\/JVI.02482-20.","DOI":"10.1128\/JVI.02482-20"},{"issue":"9","key":"10.1016\/j.vaccine.2023.01.062_b0115","doi-asserted-by":"crossref","DOI":"10.3390\/vaccines9090946","article-title":"Viral Toxin NS1 Implication in Dengue Pathogenesis Making It a Pivotal Target in Development of Efficient Vaccine","volume":"9","author":"Lebeau","year":"2021","journal-title":"Vaccines"},{"issue":"1","key":"10.1016\/j.vaccine.2023.01.062_b0120","doi-asserted-by":"crossref","first-page":"6975","DOI":"10.1038\/s41598-017-07308-3","article-title":"Antibodies Against Modified NS1 Wing Domain Peptide Protect Against Dengue Virus Infection","volume":"7","author":"Lai","year":"2017","journal-title":"Sci Rep"},{"issue":"3","key":"10.1016\/j.vaccine.2023.01.062_b0125","doi-asserted-by":"crossref","first-page":"e92495","DOI":"10.1371\/journal.pone.0092495","article-title":"Protection against dengue virus infection in mice by administration of antibodies against modified nonstructural protein 1","volume":"9","author":"Wan","year":"2014","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.vaccine.2023.01.062_b0130","doi-asserted-by":"crossref","first-page":"e1010469","DOI":"10.1371\/journal.ppat.1010469","article-title":"Therapeutic efficacy of humanized monoclonal antibodies targeting dengue virus nonstructural protein 1 in the mouse model","volume":"18","author":"Tien","year":"2022","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.vaccine.2023.01.062_b0135","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaa3787","article-title":"Dengue virus NS1 triggers endothelial permeability and vascular leak that is prevented by NS1 vaccination","author":"Beatty","year":"20157304304141","journal-title":"Sci Transl Med"},{"issue":"1","key":"10.1016\/j.vaccine.2023.01.062_b0140","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.jcv.2006.04.010","article-title":"Antibodies from patients with dengue viral infection mediate cellular cytotoxicity","volume":"37","author":"Garc\u00eda","year":"2006","journal-title":"J Clin Virol"},{"issue":"8","key":"10.1016\/j.vaccine.2023.01.062_b0145","doi-asserted-by":"crossref","first-page":"2834","DOI":"10.4049\/jimmunol.1601523","article-title":"Therapeutic Effects of Monoclonal Antibody against Dengue Virus NS1 in a STAT1 Knockout Mouse Model of Dengue Infection","volume":"199","author":"Wan","year":"2017","journal-title":"J Immunol"},{"issue":"11","key":"10.1016\/j.vaccine.2023.01.062_b0150","doi-asserted-by":"crossref","first-page":"9726","DOI":"10.1074\/jbc.M110.170993","article-title":"Molecular mimicry of human endothelial cell antigen by autoantibodies to nonstructural protein 1 of dengue virus","volume":"286","author":"Liu","year":"2011","journal-title":"J Biol Chem"},{"issue":"3","key":"10.1016\/j.vaccine.2023.01.062_b0155","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.4049\/jimmunol.0800672","article-title":"Deletion of the C-terminal region of dengue virus nonstructural protein 1 (NS1) abolishes anti-NS1-mediated platelet dysfunction and bleeding tendency","volume":"183","author":"Chen","year":"2009","journal-title":"J Immunol"},{"issue":"43","key":"10.1016\/j.vaccine.2023.01.062_b0160","doi-asserted-by":"crossref","first-page":"6814","DOI":"10.1016\/j.vaccine.2020.08.021","article-title":"Nanodelivery system enhances the immunogenicity of dengue-2 nonstructural protein 1, DENV-2 NS1","volume":"38","author":"Jearanaiwitayakul","year":"2020","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2023.01.062_b0165","first-page":"1","article-title":"Whole inactivated dengue virus-loaded trimethyl chitosan nanoparticle-based vaccine: immunogenic properties in ex vivo and in vivo models","author":"Jearanaiwitayakul","year":"2021","journal-title":"Hum Vaccin Immunother"},{"issue":"7","key":"10.1016\/j.vaccine.2023.01.062_b0170","doi-asserted-by":"crossref","first-page":"768","DOI":"10.3390\/vaccines9070768","article-title":"Intranasal Administration of RBD Nanoparticles Confers Induction of Mucosal and Systemic Immunity against SARS-CoV-2","volume":"9","author":"Jearanaiwitayakul","year":"2021","journal-title":"Vaccines"},{"issue":"11","key":"10.1016\/j.vaccine.2023.01.062_b0175","doi-asserted-by":"crossref","DOI":"10.3390\/v13112202","article-title":"Peritoneal Administration of a Subunit Vaccine Encapsulated in a Nanodelivery System Not Only Augments Systemic Responses against SARS-CoV-2 but Also Stimulates Responses in the Respiratory Tract","volume":"13","author":"Jearanaiwitayakul","year":"2021","journal-title":"Viruses"},{"issue":"7","key":"10.1016\/j.vaccine.2023.01.062_b0180","doi-asserted-by":"crossref","DOI":"10.1099\/jgv.0.001768","article-title":"Mice immunized with trimethyl chitosan nanoparticles containing DENV-2 envelope domain III elicit neutralizing antibodies with undetectable antibody-dependent enhancement activity","volume":"103","author":"Seesen","year":"2022","journal-title":"J Gen Virol"},{"issue":"8","key":"10.1016\/j.vaccine.2023.01.062_b0185","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1111\/1348-0421.12497","article-title":"EDIII-DENV3 nanospheres drive immature dendritic cells into a mature phenotype in an in vitro model","volume":"61","author":"Nantachit","year":"2017","journal-title":"Microbiol Immunol"},{"issue":"1\u20132","key":"10.1016\/j.vaccine.2023.01.062_b0190","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S0022-1759(98)00170-7","article-title":"A statistically defined endpoint titer determination method for immunoassays","volume":"221","author":"Frey","year":"1998","journal-title":"J Immunol Methods"},{"key":"10.1016\/j.vaccine.2023.01.062_b0195","doi-asserted-by":"crossref","unstructured":"Juraska M, Magaret CA, Shao J, Carpp LN, Fiore-Gartland AJ, Benkeser D, et al. Viral genetic diversity and protective efficacy of a tetravalent dengue vaccine in two phase 3 trials. Proceedings of the National Academy of Sciences. 2018;115(36):E8378 DOI: 10.1073\/pnas.1714250115.","DOI":"10.1073\/pnas.1714250115"},{"issue":"6","key":"10.1016\/j.vaccine.2023.01.062_b0200","doi-asserted-by":"crossref","first-page":"2701","DOI":"10.1128\/JVI.78.6.2701-2710.2004","article-title":"Interferon-Dependent Immunity Is Essential for Resistance to Primary Dengue Virus Infection in Mice, Whereas T- and B-Cell-Dependent Immunity Are Less Critical","volume":"78","author":"Shresta","year":"2004","journal-title":"J Virol"},{"issue":"6179","key":"10.1016\/j.vaccine.2023.01.062_b0205","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/334255a0","article-title":"Regulation of antibody isotype secretion by subsets of antigen-specific helper T cells","volume":"334","author":"Stevens","year":"1988","journal-title":"Nature"},{"issue":"13","key":"10.1016\/j.vaccine.2023.01.062_b0210","doi-asserted-by":"crossref","DOI":"10.1172\/JCI147066","article-title":"Dengue vaccine breakthrough infections reveal properties of neutralizing antibodies linked to protection","volume":"131","author":"Henein","year":"2021","journal-title":"J Clin Invest"},{"key":"10.1016\/j.vaccine.2023.01.062_b0215","doi-asserted-by":"crossref","unstructured":"Fibriansah G, Ibarra KD, Ng TS, Smith SA, Tan JL, Lim XN, et al. DENGUE VIRUS. Cryo-EM structure of an antibody that neutralizes dengue virus type 2 by locking E protein dimers. Science (New York, NY). 2015;349(6243):88-91 DOI: 10.1126\/science.aaa8651.","DOI":"10.1126\/science.aaa8651"},{"issue":"31","key":"10.1016\/j.vaccine.2023.01.062_b0220","doi-asserted-by":"crossref","first-page":"E4256","DOI":"10.1073\/pnas.1505956112","article-title":"Dengue virus infection elicits highly polarized CX3CR1+ cytotoxic CD4+ T cells associated with protective immunity","volume":"112","author":"Weiskopf","year":"2015","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.vaccine.2023.01.062_b0225","doi-asserted-by":"crossref","unstructured":"Weiskopf D, Angelo MA, de Azeredo EL, Sidney J, Greenbaum JA, Fernando AN, et al. Comprehensive analysis of dengue virus-specific responses supports an HLA-linked protective role for CD8+ T cells. Proceedings of the National Academy of Sciences. 2013;110(22):E2046 DOI: 10.1073\/pnas.1305227110.","DOI":"10.1073\/pnas.1305227110"},{"key":"10.1016\/j.vaccine.2023.01.062_b0230","doi-asserted-by":"crossref","first-page":"2125 -","DOI":"10.3389\/fimmu.2019.02125","article-title":"Human T Cell Response to Dengue Virus Infection","volume":"10","author":"Tian","year":"2019","journal-title":"Front Immunol"},{"issue":"20","key":"10.1016\/j.vaccine.2023.01.062_b0235","doi-asserted-by":"crossref","first-page":"3695","DOI":"10.1016\/j.vaccine.2011.03.002","article-title":"Synthetic peptides containing B- and T-cell epitope of dengue virus-2 E domain III provoked B- and T-cell responses","volume":"29","author":"Li","year":"2011","journal-title":"Vaccine"},{"issue":"12","key":"10.1016\/j.vaccine.2023.01.062_b0240","doi-asserted-by":"crossref","first-page":"e0145717","DOI":"10.1371\/journal.pone.0145717","article-title":"The Immunodominance Change and Protection of CD4+ T-Cell Responses Elicited by an Envelope Protein Domain III-Based Tetravalent Dengue Vaccine in Mice","volume":"10","author":"Chen","year":"2015","journal-title":"PLoS One"},{"issue":"10","key":"10.1016\/j.vaccine.2023.01.062_b0245","doi-asserted-by":"crossref","first-page":"6540","DOI":"10.1128\/jvi.70.10.6540-6546.1996","article-title":"Multiple specificities in the murine CD4+ and CD8+ T-cell response to dengue virus","volume":"70","author":"Rothman","year":"1996","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2023.01.062_b0250","doi-asserted-by":"crossref","first-page":"1522 -","DOI":"10.3389\/fimmu.2019.01522","article-title":"T Cell Responses Induced by DNA Vaccines Based on the DENV2 E and NS1 Proteins in Mice: Importance in Protection and Immunodominant Epitope Identification","volume":"10","author":"Pinto","year":"2019","journal-title":"Front Immunol"},{"issue":"9","key":"10.1016\/j.vaccine.2023.01.062_b0255","doi-asserted-by":"crossref","first-page":"e0163240","DOI":"10.1371\/journal.pone.0163240","article-title":"Aspects of T Cell-Mediated Immunity Induced in Mice by a DNA Vaccine Based on the Dengue-NS1 Antigen after Challenge by the Intracerebral Route","volume":"11","author":"Oliveira","year":"2016","journal-title":"PLoS One"},{"issue":"9","key":"10.1016\/j.vaccine.2023.01.062_b0260","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1093\/infdis\/jir012","article-title":"Intracellular Cytokine Production by Dengue Virus\u2013specific T cells Correlates with Subclinical Secondary Infection","volume":"203","author":"Hatch","year":"2011","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2023.01.062_b0265","doi-asserted-by":"crossref","first-page":"93 -","DOI":"10.3389\/fimmu.2014.00093","article-title":"T-cell immunity to infection with dengue virus in humans","volume":"5","author":"Weiskopf","year":"2014","journal-title":"Front Immunol"},{"key":"10.1016\/j.vaccine.2023.01.062_b0270","doi-asserted-by":"crossref","first-page":"7959","DOI":"10.2147\/IJN.S165876","article-title":"Novel application of trimethyl chitosan as an adjuvant in vaccine delivery","volume":"13","author":"Malik","year":"2018","journal-title":"Int J Nanomed"},{"issue":"5","key":"10.1016\/j.vaccine.2023.01.062_b0275","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1016\/j.ymthe.2022.01.013","article-title":"Immune profile and responses of a novel dengue DNA vaccine encoding an EDIII-NS1 consensus design based on Indo-African sequences","volume":"30","author":"Sankaradoss","year":"2022","journal-title":"Mol Ther"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X23000968?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X23000968?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T11:24:00Z","timestamp":1759404240000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X23000968"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":55,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["S0264410X23000968"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2023.01.062","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A bivalent form of nanoparticle-based dengue vaccine stimulated responses that potently eliminate both DENV-2 particles and DENV-2-infected cells","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2023.01.062","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}